02:57 PM EDT, 06/26/2024 (MT Newswires) -- The efficacy of Moderna's ( MRNA ) RSV vaccine drops sharply in the second year and is lower than that of rival vaccines, according to the Centers for Disease Control and Prevention.

Moderna's ( MRNA ) RSV shot dropped from 55% efficacy over the first 12 months to 36% in year two in patients with at least three "lower respiratory" symptoms of RSV. Meanwhile, Pfizer's ( PFE ) shot declined from 86% efficacy in year one to 74% in year two, while GSK's (GSK) fell from 79% to 59%, according to a CDC presentation.

Moderna ( MRNA ), Pfizer ( PFE ) and GSK did not immediately respond to MT Newswires' requests for comment.

Price: 125.10, Change: -12.51, Percent Change: -9.09